Cite this answer
Leuphasyl: quick citable summary
Leuphasyl is listed by PeptaHub as a skin & beauty peptide with a unregulated legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Leuphasyl: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/leuphasyl. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/leuphasyl.
What is Leuphasyl?
Leuphasyl (Pentapeptide-18) is a synthetic enkephalin analog that modulates calcium channels at neuromuscular junctions to relax expression wrinkles. It acts upstream of botulinum toxin without a frozen appearance and pairs with Argireline for synergy.
Overview
Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu) developed by Lipotec as a cosmeceutical anti-wrinkle active. Classified under the INCI name Pentapeptide-18, it is an enkephalin analog that modulates calcium channel activity in nerve terminals. It is widely used in prestige anti-aging serums and eye creams, frequently combined with Argireline (Acetyl Hexapeptide-3) for synergistic wrinkle-relaxing effects without injection.
Mechanism of action
Leuphasyl mimics endogenous enkephalins by binding to opioid receptors on the presynaptic membrane of neuromuscular junctions. Receptor binding triggers a conformational change that initiates an intracellular cascade reducing nerve cell excitability. This dampens the calcium-dependent vesicular release of acetylcholine at the neuromuscular junction, attenuating the intensity of facial muscle contractions that produce expression lines. Unlike botulinum toxin, Leuphasyl acts upstream at the receptor level rather than by cleaving SNARE proteins, preserving partial muscle motility and avoiding the frozen appearance associated with injections. When formulated alongside Argireline, which operates via a distinct SNARE-complex interference pathway, the two peptides produce additive wrinkle reduction exceeding either ingredient alone.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| anti-wrinkle topical application | topical | 1–5 % | twice daily | Applied in finished formulation at 1–5% concentration. Manufacturer recommends combining with Argireline at equal concentration for enhanced effect. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Leuphasyl research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
Manufacturer-sponsored (Lipotec) split-face studies report reductions in crow's-foot wrinkle depth after twice-daily topical application versus vehicle control, and describe receptor-mediated modulation of calcium channels consistent with enkephalin activity. No independent peer-reviewed clinical trials of Leuphasyl exist as of 2026; the efficacy evidence base is primarily manufacturer-sponsored and has not been verified against indexed literature.
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Leuphasyl for synergistic effects.
Legal status
Sold as a cosmetic active ingredient worldwide. No regulatory restrictions apply in the US, EU, or most jurisdictions. Available OTC in serums, creams, and eye products. Not classified as a drug.
Sourcing & access
Research compound
Leuphasyl is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Leuphasyl is a synthetic pentapeptide with the sequence Tyr-D-Ala-Gly-Phe-Leu, developed by Lipotec and classified as Pentapeptide-18 under INCI. It is a cosmetic anti-wrinkle active that mimics endogenous enkephalins, binding presynaptic opioid receptors at neuromuscular junctions to reduce the intensity of facial muscle contractions that produce expression lines.
Leuphasyl binds opioid receptors on presynaptic membranes at neuromuscular junctions, dampening calcium-dependent acetylcholine release and attenuating facial muscle contractions. Unlike botulinum toxin, it acts at the receptor level rather than cleaving SNARE proteins, preserving partial muscle motility.
Leuphasyl is sold as an unregulated cosmetic active ingredient worldwide with no prescription required. Side effects are rare and limited to skin irritation at high concentrations and very rare contact sensitization.
Leuphasyl provides a milder, non-injectable alternative to botulinum toxin for expression wrinkles. Clinical studies show statistically significant wrinkle reduction, but the effect is less dramatic than injectable Botox. It is often combined with Argireline for enhanced results.